公开(公告)号：EP2529758A2

公开(公告)日：2012-12-05

申请号：EP12004280.9

申请日：2004-01-27

申请人： Endocyte, Inc.

发明人： Vlahov, Iontcho, Radoslavov ,  Leamon, Christopher, Paul ,  Parker, Matthew, A. ,  Howard, Stephen, J. ,  Santhapuram, Hari, Krishna ,  Satyam, Apparao ,  Reddy, Joseph, Anand

IPC分类号： A61K47/48 ,  A61P35/00

CPC分类号： A61K47/48569 ,  A61K47/48384 ,  A61K47/484 ,  A61K47/48715 ,  A61K47/551 ,  A61K47/65 ,  A61K47/6803 ,  A61K47/6807 ,  A61K47/6851 ,  A61K47/6889 ,  C07K16/30 ,  C07K2317/55

摘要： The invention describes a vitamin receptor binding drug delivery conjugate, and preparations therefor. The drug delivery conjugate consists of a vitamin receptor binding moiety, a bivalent linker (L), and a drug. The vitamin receptor binding moiety is a vitamin, or a vitamin receptor binding analog or a derivative thereof, and the drug includes analogs or derivatives thereof. The vitamin receptor binding moiety is covalently linked to the bivalent linker, and the drug, or the analog or the derivative thereof, is covalently linked to the bivalent linker, wherein the bivalent linker, where the bivalent linker (L) comprises one or more spacer linkers, releasable linkers, and heteroatom linkers. Methods and pharmaceutical compositions for eliminating pathogenic cell populations using the drug delivery conjugate are also described.

摘要翻译： 本发明描述了维生素受体结合药物递送缀合物及其制剂。 药物递送缀合物由维生素受体结合部分，二价连接基（L）和药物组成。 维生素受体结合部分是维生素或维生素受体结合类似物或其衍生物，药物包括其类似物或衍生物。 维生素受体结合部分与二价连接体共价连接，并且药物或其类似物或衍生物与二价连接体共价连接，其中二价连接体（其中二价连接体（L）包含一个或多个间隔区 连接子，可释放连接子和杂原子连接子。 还描述了使用药物递送缀合物去除致病细胞群的方法和药物组合物。

公开(公告)号：EP2552483A1

公开(公告)日：2013-02-06

申请号：EP11763313.1

申请日：2011-03-29

申请人： Immunomedics, Inc.

发明人： CHANG, Chien-Hsing ,  GOLDENBERG, David, M.

IPC分类号： A61K39/395

CPC分类号： C07K16/2833 ,  A61K31/4965 ,  A61K47/484 ,  A61K47/48423 ,  A61K47/4843 ,  A61K47/6807 ,  A61K47/6813 ,  A61K47/6815 ,  A61K47/6849 ,  A61K47/6881 ,  A61K47/6885 ,  C07K16/18 ,  C07K16/2803 ,  C07K16/2851 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/30 ,  C07K16/3007 ,  C07K16/3092 ,  C07K16/44 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/51 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/734 ,  C07K2317/75 ,  C07K2317/77 ,  C07K2319/70 ,  C12N15/113 ,  C12N2310/14 ,  C12N2310/3513 ,  C12N2320/32 ,  Y02A50/403

摘要： Disclosed herein are methods and compositions comprising anti-CD74 and/or anti-HLA-DR antibodies for treatment of GVHD and other immune dysfunction diseases. In preferred embodiments, the anti-CD74 and/or anti-HLA-DR antibodies are effective to deplete antigen-presenting cells, such as dendritic cells. Most preferably, administration of the therapeutic compositions depletes all subsets of APCs, including mDCs, pDCs, B cells and monocytes, without significant depletion of T cells. In alternative embodiments, administration of the therapeutic compositions suppresses proliferation of allo-reactive T cells, while preserving cytomegalovirus (CMV)-specific, CD8+ memory T cells. The compositions and methods provide a novel conditioning regimen for preventing aGVHD and/or treating chronic GVHD, without altering preexisting anti-viral immunity.

摘要翻译： 本文公开了用于治疗GVHD和其他免疫功能障碍疾病的包含抗CD74和/或抗HLA-DR抗体的方法和组合物。 在优选的实施方案中，抗CD74和/或抗HLA-DR抗体有效消除抗原呈递细胞如树突细胞。 最优选地，治疗组合物的施用耗尽了APC的所有子集，包括mDC，pDC，B细胞和单核细胞，而没有显着耗尽T细胞。 在替代实施方案中，治疗组合物的施用抑制同种异体反应性T细胞的增殖，同时保留巨细胞病毒（CMV）特异性CD8 +记忆T细胞。 该组合物和方法提供了用于预防aGVHD和/或治疗慢性GVHD的新型预处理方案，而不改变预先存在的抗病毒免疫性。

公开(公告)号：EP2517729A3

公开(公告)日：2013-01-02

申请号：EP12004279.1

申请日：2004-01-27

申请人： Endocyte, Inc.

发明人： Vlahov, Iontcho, Radoslavov ,  Leamon, Christopher, Paul ,  Parker, Matthew, A. ,  Howard, Stephen, J. ,  Santhapuram, Hari, Krishna ,  Satyam, Apparao ,  Reddy, Joseph, Anand

IPC分类号： A61K47/48 ,  A61P35/00

CPC分类号： A61K47/48569 ,  A61K47/48384 ,  A61K47/484 ,  A61K47/48715 ,  A61K47/551 ,  A61K47/65 ,  A61K47/6803 ,  A61K47/6807 ,  A61K47/6851 ,  A61K47/6889 ,  C07K16/30 ,  C07K2317/55

摘要： The invention describes a vitamin receptor binding drug delivery conjugate, and preparations therefor. The drug delivery conjugate consists of a vitamin receptor binding moiety, a bivalent linker (L), and a drug. The vitamin receptor binding moiety is a vitamin, or a vitamin receptor binding analog or a derivative thereof, and the drug includes analogs or derivatives thereof. The vitamin receptor binding moiety is covalently linked to the bivalent linker, and the drug, or the analog or the derivative thereof, is covalently linked to the bivalent linker, wherein the bivalent linker, where the bivalent linker (L) comprises one or more spacer linkers, releasable linkers, and heteroatom linkers. Methods and pharmaceutical compositions for eliminating pathogenic cell populations using the drug delivery conjugate are also described.

公开(公告)号：EP2475391A1

公开(公告)日：2012-07-18

申请号：EP10816084.7

申请日：2010-09-09

申请人： Centrose, LLC

发明人： PRUDENT, James R. ,  THORSON, Jon S. ,  BOLLETTIERI, Jill, Hutchinson ,  HUTCHINSON, Charles B.

IPC分类号： A61K39/395 ,  C12P21/00

CPC分类号： A61K47/484 ,  A61K31/704 ,  A61K31/7052 ,  A61K47/557 ,  A61K47/60 ,  A61K47/6803 ,  A61K47/6807 ,  A61K47/6843 ,  A61K47/6849 ,  A61K47/6851 ,  C07K16/28 ,  C07K2317/92

摘要： The present invention relates to, inter alia, extracellular drug conjugates (EDC) in which an antibody or other targeting agent (e.g. a targeting moiety) is linked to a drug through a linker (e.g. a non-cleavable linker). These conjugates are useful in the treatment of disease and/or as a tool in the evaluation of biological systems.

摘要翻译： 本发明特别涉及细胞外药物偶联物（EDC），其中抗体或其它靶向剂（例如靶向部分）通过接头（例如不可裂解的接头）与药物连接。 这些缀合物可用于治疗疾病和/或作为生物系统评估的工具。

公开(公告)号：EP3169707A4

公开(公告)日：2018-01-24

申请号：EP15818722

申请日：2015-07-09

申请人： UNIV CALIFORNIA

发明人： LIU BIN

IPC分类号： C07K16/30 ,  A61K31/47 ,  A61K31/7088 ,  A61K47/50 ,  A61K47/68 ,  A61K49/00 ,  C07K16/00 ,  C07K16/28 ,  C40B40/10 ,  G01N33/533 ,  G01N33/574 ,  G01N33/68

CPC分类号： C07K16/30 ,  A61K45/06 ,  A61K47/484 ,  A61K47/48438 ,  A61K47/48569 ,  A61K47/6801 ,  A61K47/6851 ,  A61K47/6889 ,  A61K49/00 ,  C07K16/005 ,  C07K16/2866 ,  C07K16/3069 ,  C07K2317/10 ,  C07K2317/21 ,  C07K2317/32 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/77 ,  C12N15/1037 ,  G01N33/574 ,  G01N33/6854

摘要： Methods are provided for identifying and selecting antibodies that are internalized into cells via the macropinocytosis pathway. Additionally antibodies that are internalized via this pathway are provided as well as immunoconjugates comprising such antibodies.

公开(公告)号：EP2475391A4

公开(公告)日：2015-06-03

申请号：EP10816084

申请日：2010-09-09

申请人： CT SE LLC

发明人： PRUDENT JAMES R ,  THORSON JON S ,  BOLLETTIERI JILL HUTCHINSON ,  HUTCHINSON CHARLES B

IPC分类号： A61K39/395 ,  C12P21/00

CPC分类号： A61K47/484 ,  A61K31/704 ,  A61K31/7052 ,  A61K47/557 ,  A61K47/60 ,  A61K47/6803 ,  A61K47/6807 ,  A61K47/6843 ,  A61K47/6849 ,  A61K47/6851 ,  C07K16/28 ,  C07K2317/92

摘要： The present invention relates to, inter alia, extracellular drug conjugates (EDC) in which an antibody or other targeting agent (e.g. a targeting moiety) is linked to a drug through a linker (e.g. a non-cleavable linker). These conjugates are useful in the treatment of disease and/or as a tool in the evaluation of biological systems.

公开(公告)号：EP1592457A4

公开(公告)日：2010-09-08

申请号：EP04705573

申请日：2004-01-27

申请人： ENDOCYTE INC

发明人： VLAHOV IONTCHO RADOSLAVOV ,  LEAMON CHRISTOPHER PAUL ,  PARKER MATTHEW A ,  HOWARD STEPHEN J ,  SANTHAPURAM HARI KRISHNA ,  SATYAM APPARAO ,  REDDY JOSEPH ANAND

IPC分类号： A61K20060101 ,  A61K39/395 ,  A61K51/00 ,  A61K51/08 ,  A61M36/14 ,  C07K16/46 ,  A61K47/48 ,  A61P35/00

CPC分类号： A61K47/48569 ,  A61K47/48384 ,  A61K47/484 ,  A61K47/48715 ,  A61K47/551 ,  A61K47/65 ,  A61K47/6803 ,  A61K47/6807 ,  A61K47/6851 ,  A61K47/6889 ,  C07K16/30 ,  C07K2317/55

公开(公告)号：EP2552483A4

公开(公告)日：2013-09-25

申请号：EP11763313

申请日：2011-03-29

申请人： IMMUNOMEDICS INC

发明人： CHANG CHIEN-HSING ,  GOLDENBERG DAVID M

IPC分类号： A61K39/395 ,  C07K16/28 ,  C07K19/00

CPC分类号： C07K16/2833 ,  A61K31/4965 ,  A61K47/484 ,  A61K47/48423 ,  A61K47/4843 ,  A61K47/6807 ,  A61K47/6813 ,  A61K47/6815 ,  A61K47/6849 ,  A61K47/6881 ,  A61K47/6885 ,  C07K16/18 ,  C07K16/2803 ,  C07K16/2851 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/30 ,  C07K16/3007 ,  C07K16/3092 ,  C07K16/44 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/51 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/734 ,  C07K2317/75 ,  C07K2317/77 ,  C07K2319/70 ,  C12N15/113 ,  C12N2310/14 ,  C12N2310/3513 ,  C12N2320/32

摘要： Disclosed herein are methods and compositions comprising anti-CD74 and/or anti-HLA-DR antibodies for treatment of GVHD and other immune dysfunction diseases. In preferred embodiments, the anti-CD74 and/or anti-HLA-DR antibodies are effective to deplete antigen-presenting cells, such as dendritic cells. Most preferably, administration of the therapeutic compositions depletes all subsets of APCs, including mDCs, pDCs, B cells and monocytes, without significant depletion of T cells. In alternative embodiments, administration of the therapeutic compositions suppresses proliferation of allo-reactive T cells, while preserving cytomegalovirus (CMV)-specific, CD8+ memory T cells. The compositions and methods provide a novel conditioning regimen for preventing aGVHD and/or treating chronic GVHD, without altering preexisting anti-viral immunity.

摘要翻译： 本文公开了包含用于治疗GVHD和其他免疫功能障碍疾病的抗CD74和/或抗HLA-DR抗体的方法和组合物。 在优选的实施方案中，抗CD74和/或抗HLA-DR抗体有效地消耗抗原呈递细胞，例如树突状细胞。 最优选地，治疗组合物的施用消耗了APC的所有子集，包括mDC，pDC，B细胞和单核细胞，而没有T细胞的显着消耗。 在替代实施方案中，施用治疗组合物抑制同种异体反应性T细胞的增殖，同时保留巨细胞病毒（CMV）特异性CD8 +记忆T细胞。 组合物和方法提供了用于预防aGVHD和/或治疗慢性GVHD的新型调节方案，而不改变预先存在的抗病毒免疫。

公开(公告)号：EP1592457B1

公开(公告)日：2012-07-25

申请号：EP04705573.6

申请日：2004-01-27

申请人： Endocyte, Inc.

发明人： VLAHOV, Iontcho, Radoslavov ,  LEAMON, Christopher, Paul ,  PARKER, Matthew, A. ,  HOWARD, Stephen, J. ,  SANTHAPURAM, Hari, Krishna ,  SATYAM, Apparao ,  REDDY, Joseph, Anand

IPC分类号： A61K47/48 ,  A61P35/00

CPC分类号： A61K47/48569 ,  A61K47/48384 ,  A61K47/484 ,  A61K47/48715 ,  A61K47/551 ,  A61K47/65 ,  A61K47/6803 ,  A61K47/6807 ,  A61K47/6851 ,  A61K47/6889 ,  C07K16/30 ,  C07K2317/55

摘要： The invention describes a vitamin receptor binding drug delivery conjugate, and preparations therefor. The drug delivery conjugate consists of a vitamin receptor binding moiety, a bivalent linker (L), and a drug. The vitamin receptor binding moiety is a vitamin, or a vitamin receptor binding analog or a derivative thereof, and the drug includes analogs or derivatives thereof. The vitamin receptor binding moiety is covalently linked to the bivalent linker, and the drug, or the analog or the derivative thereof, is covalently linked to the bivalent linker, wherein the bivalent linker (L) comprises one or more spacer linkers, releasable linkers, and heteroatom linkers. Methods and pharmaceutical compositions for eliminating pathogenic cell populations using the drug delivery conjugate are also described.

公开(公告)号：EP2393504A2

公开(公告)日：2011-12-14

申请号：EP10716268.7

申请日：2010-02-08

申请人： Freie Universität Berlin

发明人： ERDMANN, Volker ,  WYSZKO, Eliza

IPC分类号： A61K38/00

CPC分类号： A61K47/484 ,  A61K31/7088 ,  A61K31/7105 ,  A61K47/6807 ,  C12N15/111 ,  C12N2310/121 ,  C12N2310/30

摘要： The invention relates to the use of an L-ribozyme, which is capable of splitting an L-RNA in the region of a target sequence of the L-RNA, in order to produce a pharmaceutical composition for treating undesired physiological adverse reactions due to the administration of a therapeutic molecule containing the L-RNA. Alternatively, an endogenous target RNA may also be split by the L-ribozyme.